openPR Logo
Press release

Plexiform Neurofibroma Market share will expand till 2024    

Plexiform Neurofibroma Market share will expand till 2024    

One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body.

Request Sample Copy of the Report@

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14783

The most commonly observed tumor is cutaneous neurofibroma, plexiform neurofibroma market is characterized by the formation of small bumps under the skin, which proliferate in both size and number. Cutaneous neurofibromas though cause sensitivity and cosmetic issues, they cause negligible medical problems.

Another type of tumor that commonly affects NF1 patients is plexiform neurofibromas (pNFs) market. It is a benign tumor affecting peripheral nerves that follows the neural element proliferation. Around half of the NH1 affected patient population is usually prone to pNF. This type of tumor includes a range of cell types, such as mast cells, Schwann cells, macrophages, fibroblasts, neuronal axons, and perineural cells. It may also contain collagen and other similar extracellular matrix materials.

Plexiform neurofibrosis can occur anywhere in a body and tumors may continue to grow throughout the life span of a patient. If the neurofibroma converts into a malignant sarcoma or key organs of a body are compressed, it may also result in a deadly outcome. Among all the implictions of NF1, plexiform neurofibromas are the most exhaustive and widely observed. In addition to causing substantial morbidity, nPNF may result in disability, disfiguring, and functional impairment as well.

Rarely, plexiform neurofibromas may result in abnormal functioning of eyes, dysplasias, cognitive deficits, and cardiovascular disorders. Moreover, there are higher chances of acquiring gliomas, leukemias, neuroendocrine tumors, and sometimes breats cancer in females over 50 years of age.

As pNFs may affect any part of a human body, they generally lead to clinical complications. Those occurred in the areas near neck or head are especially complicated because they result in a range of functional deficits and facial feature disfiguring. Large tumor resections often come with a risk of functional destruction and neurological complications.

MRI and CT scans are used for primary diagnosis of pNFs. When it comes to selecting the right treatment option, medication is not considered the only option as it is proved to be inefficient in treating plexiform neurofibroma. Surgery is the only relatively effective therapy available today. Surgical excision starts with de-bulking, and does not assure cure. Tumors continue to regrow post-surgery and patients have to undergo multiple surgical interventions. Rapid tumor growth, tumor size and location, tumor’s microscopic extension, and neural involvement collectively make it difficult to implement a surgical procedure.

Combination chemotherapy is already being used against plexiform neurofibromas. Drugs, which are used in combination with chemotherapy serve to prevent the proliferation of tumors. Sometimes, tumors may also die. However, the efficacy of combination therapy is not considered a completely reliable option to treat pNF patients.

Other possible methods of treatment are being researched on but nothing substantial has been found yet, in terms of plexiform neurofibroma treatment. Being associated with neurofibromatosis type I, pNFs either reoccur or transform in a malignant stage. Moreover, the tumors are non-radioactive and thus chemotherapy also shows a limited impact. Evaluating clinical trials is quite challenging in case of plexiform neurofibromas, as they develop in an unpredictable manner, making it difficult to examine the objective response. Emergence of innovative techniques of neuroimaging might play a vital role in clinical trials and help to discover highly potential treatment options thereby.

Request TOC of the Report@

 http://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=14783

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
Middle East and Africa (GCC, Southern Africa, North Africa)

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Plexiform Neurofibroma Market share will expand till 2024     here

News-ID: 720760 • Views:

More Releases from Transparency Market Research

Acromegaly Treatment Market to Reach USD 3.1 Billion by 2035, Driven by Diagnostic Advancements, Oral Drug Innovations, and Rising Disease Awareness | TMR
Acromegaly Treatment Market to Reach USD 3.1 Billion by 2035, Driven by Diagnost …
The global Acromegaly Treatment Market is experiencing a significant transformation as improved early diagnosis, innovative therapeutic formulations, and regulatory support converge to expand patient access and drive substantial growth. According to the latest industry analysis, the global market, valued at US$ 1.5 billion in 2024, is projected to reach US$ 3.1 billion by 2035, progressing at a CAGR of 6.7% from 2025 to 2035. Gain a preview of important insights from
Forensic Genomics Market Projected to Surge to USD 2.4 Billion by 2035 as NGS, AI/ML Bioinformatics and Portable DNA Devices Transform Criminal Investigations | TMR
Forensic Genomics Market Projected to Surge to USD 2.4 Billion by 2035 as NGS, A …
The global Forensic Genomics Market is undergoing a period of accelerated transformation and expansion as next-generation sequencing (NGS), advanced PCR workflows, and AI/ML-driven bioinformatics redefine the capabilities of modern forensic investigations. According to the latest industry analysis, the market-valued at US$ 0.5 billion in 2024-is projected to reach approximately US$ 2.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of 14.5% between 2025 and 2035. Access key findings
Planetary Roller Screw Market to Reach USD 1.1 Billion by 2035 as Demand for High-Load, High-Precision Actuation Systems Accelerates Worldwide | TMR
Planetary Roller Screw Market to Reach USD 1.1 Billion by 2035 as Demand for Hig …
The global Planetary Roller Screw Market is poised for substantial expansion over the next decade, driven by rising demand for high-load, high-precision performance in harsh industrial environments, rapid technological advancements, and the ongoing global shift toward electrified and automated systems. According to the latest industry intelligence, the market-valued at US$ 610.0 Mn in 2024-is projected to reach US$ 1,105.0 Mn by 2035, advancing at a compound annual growth rate (CAGR)
Chemical Absorbent Cotton Market Set to Reach USD 600.1 Million by 2035 Driven by Sustainability Initiatives, Regulatory Compliance, and Rising Industrial Demand
Chemical Absorbent Cotton Market Set to Reach USD 600.1 Million by 2035 Driven b …
The global Chemical Absorbent Cotton Market is entering a phase of sustained expansion, backed by rapid industrialization, strengthened environmental regulations, and growing adoption of biodegradable absorbent solutions across healthcare, chemical handling, automotive, and industrial safety applications. According to the latest industry analysis, the global market-valued at US$ 340.0 million in 2024-is projected to reach US$ 600.1 million by 2035, expanding at a CAGR of 5.4% from 2025 to 2035. Access key

All 5 Releases


More Releases for NF1

The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics). DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034" offers
Plexiform Neurofibroma Market to Grow at 9.7% CAGR from 2025 to 2034
Subheadline: Rising research in neurofibromatosis type 1 (NF1), FDA approvals of MEK inhibitors, and emerging gene-editing therapies are driving strong global growth in the plexiform neurofibroma market. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72662 Introduction The Plexiform Neurofibroma Market is entering a period of rapid expansion as precision medicine and genetic therapies reshape the management of neurofibromatosis type 1 (NF1) and related tumor growth disorders. Valued at USD 410 million in 2024,
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US. Key NF1 Market Highlights * The Neurofibromatosis Type 1 treatment
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to R …
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719 Until recently, management relied on surgery, which is often
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs). Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663 Historically,